Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen

Vaccine

Volumn 32, Issue 41, 2014, Pages 5323-5329

  Oreshkova, N ^a,b   Cornelissen, L A H M ^a   de Haan, C A M ^b   Moormann, R J M ^a,b   Kortekaas, J ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Hemagglutinin; Intranasal; Nonspreading; Rift Valley fever virus; Vaccine; Vector

Indexed keywords

GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; RIFT VALLEY FEVER VIRUS VACCINE VECTOR; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; CYTOKINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA A (H1N1); MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RIFT VALLEY FEVER VIRUS; SPLEEN CELL; SPLEEN LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; TH1 CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOKINES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; REPLICON; RIFT VALLEY FEVER VIRUS; TH1 CELLS; VACCINATION;

EID: 84925883333     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.051     Document Type: Article

References (35)

1. Khromykh A.A. Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000, 2:555-569.
2. Vander Veen R.L., Harris D.L., Kamrud K.I. Alphavirus replicon vaccines. Anim Health Res Rev 2012, 13:1-9.
3. Zimmer G. RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses 2010, 2:413-434.
4. Gallei A., Pankraz A., Thiel H.J., Becher P. RNA recombination in vivo in the absence of viral replication. J Virol 2004, 78:6271-6281.
5. Raju R., Subramaniam S.V., Hajjou M. Genesis of Sindbis virus by in vivo recombination of nonreplicative RNA precursors. J Virol 1995, 69:7391-7401.
6. Lai M.M. RNA recombination in animal and plant viruses. Microbiol Rev 1992, 56:61-79.
7. Chare E.R., Gould E.A., Holmes E.C. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol 2003, 84:2691-2703.
8. Spann K.M., Collins P.L., Teng M.N. Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol 2003, 77:11201-11211.
9. Publicover J., Ramsburg E., Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005, 79:13231-13238.
10. Kortekaas J., Oreshkova N., Cobos-Jimenez V., Vloet R.P., Potgieter C.A., Moormann R.J. Creation of a nonspreading Rift Valley fever virus. J Virol 2011, 85:12622-12630.
11. Elliott R.M. The Bunyaviridae 1996, Plenum Press, New York, NY.
12. Kakach L.T., Wasmoen T.L., Collett M.S. Rift-Valley fever virus M segment - use of recombinant vaccinia viruses to study Phlebovirus gene-expression. J Virol 1988, 62:826-833.
13. Struthers J.K., Swanepoel R., Shepherd S.P. Protein-synthesis in Rift-Valley fever virus-infected cells. Virology 1984, 134:118-124.
14. Won S.Y., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007, 81:13335-13345.
15. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001, 75:1371-1377.
16. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004, 78:9798-9806.
17. Kopecky-Bromberg S.A., Palese P. Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 2009, 333:243-267.
18. Cornelissen L.A., de Leeuw O.S., Tacken M.G., Klos H.C., de Vries R.P., de Boer-Luijtze E.A., et al. Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice. PLOS ONE 2012, 7:e44447.
19. Munster V.J., de Wit E., van den Brand J.M., Herfst S., Schrauwen E.J., Bestebroer T.M., et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009, 325:481-483.
20. de Jong R.M.C., Stockhofe-Zurwieden N., Verheij E.S., de Boer-Luijtze E.A., Ruiter S.J.M., de Leeuw O.S., et al. Rapid emergence of a virulent PB2 E627K variant during adaptation of highly pathogenic avian influenza H7N7 virus to mice. Virol J 2013, 10.
21. Oreshkova N., van Keulen L., Kant J., Moormann R.J., Kortekaas J. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. PLOS ONE 2013, 8:e77461.
22. Guthe S., Kapinos L., Moglich A., Meier S., Grzesiek S., Kiefhaber T. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. J Mol Biol 2004, 337:905-915.
23. de Vries R.P., de Vries E., Bosch B.J., de Groot R.J., Rottier P.J., de Haan C.A. The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity. Virology 2010, 403:17-25.
24. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221:35-41.
25. Tamura M., Kuwano K., Kurane I., Ennis F.A. Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. J Virol 1998, 72:9404-9406.
26. Gambotto A., Dworacki G., Cicinnati V., Kenniston T., Steitz J., Tuting T., et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 2000, 7:2036-2040.
27. Morrill J.C., Peters C.J. Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine. J Infect Dis 2011, 204:617-625.
28. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
29. Weldon W.C., Wang B.Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE 2010, 5.
30. Cornelissen L.A., de Vries R.P., de Boer-Luijtze E.A., Rigter A., Rottier P.J., de Haan C.A. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS ONE 2010, 5:e10645.
31. Loeffen W.L., de Vries R.P., Stockhofe N., van Zoelen-Bos D., Maas R., Koch G., et al. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus. Vaccine 2011, 29:1545-1550.
32. Morrill J.C., Peters C.J. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. J Infect Dis 2011, 204:229-236.
33. Smith D.R., Bird B.H., Lewis B., Johnston S.C., McCarthy S., Keeney A., et al. Development of a novel nonhuman primate model for Rift Valley fever. J Virol 2012, 86:2109-2120.
34. Brown J.L., Dominik J.W., Morrissey R.L. Respiratory infectivity of a recently isolated Egyptian strain of Rift Valley fever virus. Infect Immun 1981, 33:848-853.
35. Hoogstraal H., Meegan J.M., Khalil G.M., Adham F.K. The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies. Trans R Soc Trop Med Hyg 1979, 73:624-629.